Catheter Ablation for Atrial Fibrillation in Patients with Prior Left Atrial Appendage Occlusion Device

Overview

Journal J Interv Card Electrophysiol

Publisher Springer

Date 2024 Sep 10

PMID 39256235

Authors

Jakrin Kewcharoen

Kuldeep Shah

Rahul Bhardwaj

Tahmeed Contractor

Davendra Ramsingh

Mohit K Turagam

Ravi Mandapati

Dhanunjaya Lakkireddy

Jalaj Garg

Affiliations

Soon will be listed here.

Abstract

Background: The safety and efficacy of CA for AF and left-sided atrial arrhythmias (AA) in patients with left atrial appendage occlusion (LAAO) devices are lacking.

Methods: This is a single-center retrospective registry that included all patients with prior LAAO who underwent catheter ablation for AF or left-sided atrial arrhythmia from January 2020-January 2023. The primary outcomes were procedure-related complications, device-related complications, AA recurrence, and stroke.

Results: A total of 30 patients with prior LAAO were included in the analysis (mean age 75.1 ± 7.1 years old, 50% male, mean CHADS-VASc score 4 ± 1.6, 46.7% paroxysmal AF, 73.3% had prior AF ablation, mean time to ablation 475 ± 365 days). 93.3% (n = 28) and 6.6% (n = 2) patients had ablation for AF (46.7% paroxysmal, 36.7% persistent, 10% long-standing persistent) and left-sided atrial tachycardia, respectively. 16.7% (n = 5) patients underwent ablation along the left atrial appendage ostium, and 3.3% (n = 1) underwent Vein of Marshall alcohol ablation. There were 3 (10%) peri-procedural complications (1 access hematoma and two pericardial effusions requiring intervention-none related to left atrial appendage ostium or alcohol ablation). During the mean follow-up of 440 ± 379 days, 40% (n = 12) patients had AA recurrence (91.6% AF, 8.3% atrial tachycardia), of which five patients needed repeat ablation, and two patients were readmitted for heart failure. There was no stroke or any device-related complications, including new peri-device leaks or device-related thrombosis in patients who had follow-up imaging studies (n = 11, 36.7%).

Conclusion: Catheter ablation for AF (including VoM alcohol ablation) in patients with prior LAAO devices is feasible and safe with favorable outcomes.

References

Wilber D, Pappone C, Neuzil P, de Paola A, Marchlinski F, Natale A . Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010; 303(4):333-40. DOI: 10.1001/jama.2009.2029. View

Joglar J, Chung M, Armbruster A, Benjamin E, Chyou J, Cronin E . 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2023; 149(1):e1-e156. PMC: 11095842. DOI: 10.1161/CIR.0000000000001193. View

Grimaldi-Bensouda L, Le Heuzey J, Ferrieres J, Leys D, Davy J, Martinez M . Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors. Stroke. 2021; 52(10):3121-3131. DOI: 10.1161/STROKEAHA.120.032704. View

Holmes D, Reddy V, Turi Z, Doshi S, Sievert H, Buchbinder M . Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009; 374(9689):534-42. DOI: 10.1016/S0140-6736(09)61343-X. View

Reddy V, Holmes D, Doshi S, Neuzil P, Kar S . Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011; 123(4):417-24. DOI: 10.1161/CIRCULATIONAHA.110.976449. View

Freeman J, Varosy P, Price M, Slotwiner D, Kusumoto F, Rammohan C . The NCDR Left Atrial Appendage Occlusion Registry. J Am Coll Cardiol. 2020; 75(13):1503-1518. PMC: 7205034. DOI: 10.1016/j.jacc.2019.12.040. View

Phillips K, Walker D, Humphries J . Combined catheter ablation for atrial fibrillation and Watchman® left atrial appendage occlusion procedures: Five-year experience. J Arrhythm. 2016; 32(2):119-26. PMC: 4823577. DOI: 10.1016/j.joa.2015.11.001. View

Charate R, Ahmed A, Della Rocca D, Bloom S, Garg J, Pothineni N . Evaluation of Multimodality LAA Leak Closure Methods Following Incomplete Occlusion: The LAA Leak Study. JACC Cardiovasc Interv. 2022; 15(21):2158-2170. DOI: 10.1016/j.jcin.2022.08.034. View

Di Biase L, Burkhardt J, Mohanty P, Sanchez J, Mohanty S, Horton R . Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation. 2010; 122(2):109-18. DOI: 10.1161/CIRCULATIONAHA.109.928903. View

10.

Turagam M, Lavu M, Afzal M, Vuddanda V, Jazayeri M, Parikh V . Catheter Ablation for Atrial Fibrillation in Patients With Watchman Left Atrial Appendage Occlusion Device: Results from a Multicenter Registry. J Cardiovasc Electrophysiol. 2016; 28(2):139-146. DOI: 10.1111/jce.13148. View

11.

Chen J, Chiu F, Chang S, Cheng H, Huang P, Wu C . Impact of pre-existing left atrial appendage occluder on catheter ablation of atrial fibrillation. Heart. 2023; 109(12):921-928. DOI: 10.1136/heartjnl-2022-321934. View

12.

Heeger C, Rillig A, Lin T, Mathew S, Deiss S, Lemes C . Feasibility and clinical efficacy of left atrial ablation for the treatment of atrial tachyarrhythmias in patients with left atrial appendage closure devices. Heart Rhythm. 2015; 12(7):1524-31. DOI: 10.1016/j.hrthm.2015.03.011. View

13.

Dukkipati S, Kar S, Holmes D, Doshi S, Swarup V, Gibson D . Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes. Circulation. 2018; 138(9):874-885. DOI: 10.1161/CIRCULATIONAHA.118.035090. View

14.

Walker D, Phillips K . Left atrial catheter ablation subsequent to Watchman® left atrial appendage device implantation: a single centre experience. Europace. 2015; 17(9):1402-6. DOI: 10.1093/europace/euv037. View

15.

Wintgens L, Klaver M, Swaans M, Alipour A, Balt J, van Dijk V . Left atrial catheter ablation in patients with previously implanted left atrial appendage closure devices. Europace. 2018; 21(3):428-433. DOI: 10.1093/europace/euy237. View

16.

Kar S, Hou D, Jones R, Werner D, Swanson L, Tischler B . Impact of Watchman and Amplatzer devices on left atrial appendage adjacent structures and healing response in a canine model. JACC Cardiovasc Interv. 2014; 7(7):801-9. DOI: 10.1016/j.jcin.2014.03.003. View

17.

Valderrabano M, Peterson L, Swarup V, Schurmann P, Makkar A, Doshi R . Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial. JAMA. 2020; 324(16):1620-1628. PMC: 7592031. DOI: 10.1001/jama.2020.16195. View

18.

Rodriguez-Manero M, Schurmann P, Valderrabano M . Ligament and vein of Marshall: A therapeutic opportunity in atrial fibrillation. Heart Rhythm. 2015; 13(2):593-601. PMC: 4796610. DOI: 10.1016/j.hrthm.2015.10.018. View